Cowen & Company Initiates Alnylam Pharmaceuticals With Outperform

Loading...
Loading...
Cowen & Company initiated coverage on
Alnylam Pharmaceuticals, Inc.ALNY
with a Outperform rating, acc. to sources. The target price for Alnylam Pharmaceuticals is set to $150. Alnylam Pharmaceuticals shares have gained 28.50% over the past 52 weeks, while the S&P 500 index has surged 13.51% in the same period. Alnylam Pharmaceuticals' shares closed at $104.39 yesterday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: InitiationAnalyst RatingsCowen & Company
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...